Australia is closely awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://geraldxhmb728287.thenerdsblog.com/48962171/retatrutide-australia-a-promising-breakthrough-for-obesity-treatment